# First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

> **NCT04391283** · — · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 500 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04391283
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-27
- **Primary completion:** 2022-04-26
- **Final completion:** 2024-12
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2023-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391283, "First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04391283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*